Chang J C, Gross H M
Department of Medicine, Wright State University School of Medicine, Dayton, Ohio.
Am J Med Sci. 1988 May;295(5):472-6. doi: 10.1097/00000441-198805000-00011.
Three patients with chronic idiopathic myelofibrosis have responded to busulfan treatment with an excellent hematologic remission and reversal of myelofibrosis and myeloid metaplasia. Four months after busulfan therapy all three patients showed an improvement of hematocrit and hemoglobin and reduction of the number of leukoerythroblasts. Cellular bone marrow was re-established in two patients. A decrease of hepatomegaly and splenomegaly also occurred and was well correlated with the hematologic response. In one patient, when busulfan was discontinued for about 2 years after achieving an excellent remission, hematologic relapse was accompanied by increase of hepatomegaly and splenomegaly. When busulfan treatment was resumed, hematologic response and decrease of hepatomegaly and splenomegaly reoccurred. This observation has demonstrated the beneficial effect of busulfan in chronic idiopathic myelofibrosis; therefore, the role of busulfan in the management of this disease should be further investigated.
三名慢性特发性骨髓纤维化患者对白消安治疗有反应，出现了极佳的血液学缓解，骨髓纤维化和髓外化生逆转。白消安治疗四个月后，所有三名患者的血细胞比容和血红蛋白均有所改善，幼稚白细胞数量减少。两名患者重建了细胞性骨髓。肝肿大和脾肿大也有所减轻，且与血液学反应密切相关。在一名患者中，在达到极佳缓解后停用白消安约2年，血液学复发伴有肝肿大和脾肿大增加。当重新开始白消安治疗时，再次出现血液学反应以及肝肿大和脾肿大减轻。该观察结果证明了白消安对慢性特发性骨髓纤维化的有益作用；因此，应进一步研究白消安在该疾病治疗中的作用。
